Content about Entacapone

December 20, 2012
Mylan, Orion settle Parkinson's disease drug case

Generic drug maker Mylan has settled with Orion over a drug used to treat Parkinson's disease, Mylan said Thursday

PITTSBURGH — Generic drug maker Mylan has settled with Orion over a drug used to treat Parkinson's disease, Mylan said Thursday.

The company said it reached a settlement with Orion to resolve patent litigation concerning a generic version of Orion's drug Comtan (entacapone) tablets in the 200-mg strength. The drug is used with levodopa-carbidopa therapy to treat Parkinson's patients who experience signs and symptoms of end-of-dose "wearing off."

November 27, 2012
Wockhardt receives three FDA approvals

Indian generic drug maker Wockhardt received three new drug approvals from the Food and Drug Administration, agency records show.

SILVER SPRING, Md. — Indian generic drug maker Wockhardt received three new drug approvals from the Food and Drug Administration, agency records show.

August 15, 2011
Study: Investigational GSK, Impax drug reduces Parkinson's symptoms

Patients taking an experimental treatment for Parkinson's disease experienced greater reduction in symptoms than those taking standard therapies, according to results of a late-stage clinical trial.

HAYWARD, Calif. — Patients taking an experimental treatment for Parkinson's disease experienced greater reduction in symptoms than those taking a drug already on the market, according to results of a late-stage clinical trial.

July 26, 2011
Impax enrolls patients into late-stage trial for Parkinson's treatment

The branded drugs division of Impax Labs has finished enrolling patients in a late-stage trial of a drug for Parkinson’s disease.

HAYWARD, Calif. — The branded drugs division of Impax Labs has finished enrolling patients in a late-stage trial of a drug for Parkinson’s disease.

Impax Pharmaceuticals said Tuesday that it had enrolled patients in ASCEND-PD, a phase-3 trial of IPX066 that will compare the drug with carbidopa-levodopa and entacapone in patients with advanced Parkinson’s. IPX066 is an extended-release formulation of carbidopa-levodopa in capsule form.

March 30, 2010
FDA: Stalevo may increase male patients' risk of cancer

Data from a long-term clinical trial may indicate a possible cancer risk in men taking...